See more : CGG (CGGBT.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Navidea Biopharmaceuticals, Inc. (NAVB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Navidea Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ImmunoPrecise Antibodies Ltd. (IPA) Income Statement Analysis – Financial Results
- Hearts and Minds Investments Limited (HM1.AX) Income Statement Analysis – Financial Results
- Eden Innovations Ltd (EDE.AX) Income Statement Analysis – Financial Results
- JSW Energy Limited (JSWENERGY.BO) Income Statement Analysis – Financial Results
- DNB Bank ASA (0O84.L) Income Statement Analysis – Financial Results
Navidea Biopharmaceuticals, Inc. (NAVB)
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.65K | 531.51K | 915.01K | 26.62K | 322.52K | 1.81M | 21.97M | 13.25M | 6.27M | 1.13M | 78.74K | 597.73K | 10.70M | 9.52M | 7.89M | 7.12M | 6.05M | 5.92M | 5.95M | 6.51M | 4.92M | 7.58M | 9.71M | 9.45M | 5.83M | 5.13M | 1.17M | 1.00M | 900.00K | 100.00K | 100.00K |
| Cost of Revenue | 184.95K | 198.83K | 1.05K | 6.67K | 96.64K | 3.65K | 2.30M | 1.75M | 1.59M | 332.82K | 0.00 | 0.00 | 3.21M | 3.13M | 3.01M | 3.18M | 2.63M | 2.38M | 2.34M | 3.12M | 2.35M | 4.39M | 4.63M | 3.95M | 1.40M | 1.58M | 676.77K | 500.00K | 100.00K | 5.90M | 100.00K |
| Gross Profit | -119.30K | 332.68K | 913.97K | 19.95K | 225.89K | 1.81M | 19.67M | 11.49M | 4.69M | 797.82K | 78.74K | 597.73K | 7.49M | 6.38M | 4.88M | 3.94M | 3.42M | 3.54M | 3.61M | 3.38M | 2.57M | 3.20M | 5.08M | 5.49M | 4.43M | 3.55M | 494.41K | 500.00K | 800.00K | -5.80M | 0.00 |
| Gross Profit Ratio | -181.71% | 62.59% | 99.89% | 74.95% | 70.04% | 99.80% | 89.54% | 86.76% | 74.72% | 70.56% | 100.00% | 100.00% | 70.03% | 67.07% | 61.83% | 55.30% | 56.50% | 59.86% | 60.61% | 52.00% | 52.22% | 42.17% | 52.31% | 58.13% | 75.93% | 69.27% | 42.21% | 50.00% | 88.89% | -5,800.00% | 0.00% |
| Research & Development | 5.97M | 5.14M | 4.93M | 5.34M | 4.22M | 4.51M | 8.88M | 12.79M | 16.78M | 23.71M | 16.89M | 15.15M | 9.22M | 4.97M | 4.51M | 2.87M | 3.80M | 4.03M | 2.45M | 1.89M | 2.32M | 344.68K | 472.73K | 1.31M | 12.96M | 19.66M | 16.08M | 7.80M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 7.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.85M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.31M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.96M | 7.45M | 6.69M | 6.28M | 7.70M | 11.17M | 13.01M | 17.26M | 15.54M | 15.53M | 11.18M | 9.55M | 4.58M | 3.24M | 3.41M | 2.84M | 3.08M | 3.16M | 3.15M | 3.10M | 3.27M | 2.32M | 2.96M | 8.21M | 10.55M | 11.16M | 7.75M | 3.60M | 12.00M | 2.30M | 2.90M |
| Other Expenses | 0.00 | -14.12K | -21.86K | -631.21K | 1.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 552.96K | 9.38M | 0.00 | 0.00 | 500.00K | 600.00K | 100.00K | 100.00K |
| Operating Expenses | 13.93M | 12.59M | 11.63M | 10.98M | 11.07M | 15.68M | 21.90M | 30.05M | 32.32M | 39.24M | 28.07M | 24.70M | 13.80M | 8.21M | 7.92M | 41.23M | 6.88M | 7.19M | 5.61M | 5.00M | 5.59M | 2.67M | 3.43M | 10.07M | 32.90M | 30.82M | 23.84M | 11.90M | 12.60M | 2.40M | 3.00M |
| Cost & Expenses | 14.12M | 12.59M | 11.63M | 10.99M | 11.17M | 15.69M | 24.19M | 31.80M | 33.91M | 39.57M | 28.07M | 24.70M | 17.01M | 11.34M | 10.93M | 44.42M | 9.51M | 9.56M | 7.95M | 8.12M | 7.94M | 7.05M | 8.06M | 14.03M | 34.30M | 32.39M | 24.51M | 12.40M | 12.70M | 8.30M | 3.10M |
| Interest Income | 0.00 | 6.00K | 11.34K | 25.00K | 0.00 | 0.00 | 0.00 | 0.00 | 16.10K | 18.84K | 25.04K | 25.76K | 8.80K | 18.75K | 60.86K | 70.98K | 225.47K | 226.66K | 28.87K | 9.42K | 74.26K | 127.66K | 205.96K | 0.00 | 598.83K | 0.00 | 2.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.10M | 6.36K | 0.00 | 25.29K | 30.80K | 168.97K | 4.87K | 1.27M | 3.71M | 2.78M | 1.17M | 13.33K | 554.99K | 1.53M | 1.74M | 2.28M | 1.50M | 1.35M | 334.20K | 186.91K | 31.95K | 11.10K | 24.88K | 0.00 | 189.79K | 0.00 | 83.44K | 200.00K | 100.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 95.82K | 198.83K | 190.58K | 144.51K | 150.39K | 254.59K | 501.37K | 571.42K | 500.18K | 404.18K | 200.22K | 176.54K | 223.46K | 333.75K | 408.35K | 1.81M | 1.22M | 1.29M | 856.01K | 757.78K | 796.83K | 423.12K | 392.50K | 552.96K | 1.12M | 896.52K | 652.62K | -500.00K | -600.00K | -100.00K | -100.00K |
| EBITDA | -13.88M | -11.51M | -10.64M | -10.82M | -10.85M | -13.14M | -6.87M | -21.31M | -31.52M | -38.03M | -27.79M | -24.86M | -49.10M | -35.85M | -2.48M | -2.40M | -2.83M | -2.97M | -1.14M | -853.34K | -2.22M | 955.59K | 1.67M | -4.03M | -27.20M | -26.37M | -22.97M | -11.80M | -12.10M | -8.40M | -3.10M |
| EBITDA Ratio | -21,134.32% | -2,337.93% | -1,170.60% | -41,184.60% | -1,722.58% | -541.05% | -20.54% | -114.85% | -448.72% | -3,399.73% | -35,547.39% | -3,998.82% | 345.15% | 341.96% | -27.82% | -482.39% | -36.85% | -37.03% | 1.57% | -12.95% | -45.50% | 20.93% | 17.16% | -46.74% | -469.25% | -551.70% | -1,960.93% | -1,180.00% | -1,344.44% | -8,400.00% | -3,100.00% |
| Operating Income | -14.05M | -12.06M | -10.71M | -10.96M | -10.85M | -13.88M | -2.22M | -18.55M | -27.63M | -38.44M | -27.99M | -24.10M | -6.31M | -1.82M | -3.04M | -1.76M | -3.46M | -3.64M | -2.00M | -1.61M | -2.99M | -352.21K | 1.29M | -4.58M | -28.47M | -27.26M | -23.34M | -11.40M | -11.80M | -8.20M | -3.00M |
| Operating Income Ratio | -21,402.08% | -2,269.07% | -1,170.60% | -41,184.60% | -3,363.29% | -766.50% | -10.12% | -140.01% | -440.38% | -3,399.73% | -35,547.39% | -4,032.67% | -58.98% | -19.17% | -38.57% | -24.74% | -57.19% | -61.56% | -33.58% | -24.75% | -60.82% | -4.64% | 13.25% | -48.50% | -488.08% | -531.69% | -1,993.02% | -1,140.00% | -1,311.11% | -8,200.00% | -3,000.00% |
| Total Other Income/Expenses | -1.13M | 345.52K | -10.51K | 17.68K | -5.32M | -3.91M | 2.77M | -10.32M | -13.14M | -4.26M | -1.17M | -943.16K | -37.20M | 1.82M | -2.12M | -3.33M | -1.28M | -1.28M | -1.24M | -10.38K | 28.48K | 369.77K | 371.83K | 386.58K | 26.50K | 1.92M | 276.87K | 900.00K | 900.00K | 300.00K | 200.00K |
| Income Before Tax | -15.18M | -11.71M | -10.72M | -10.94M | -16.17M | -17.79M | -14.31M | -28.76M | -35.73M | -42.70M | -29.16M | -25.05M | -49.96B | -39.61B | -5.17B | -5.09B | -4.74B | -4.93B | -3.24M | -1.62M | -2.96M | 17.57K | 1.66M | -4.19M | -28.44M | -25.34M | -23.07M | -10.50M | -10.90M | -7.90M | -2.80M |
| Income Before Tax Ratio | -23,117.58% | -2,204.06% | -1,171.75% | -41,118.20% | -5,013.18% | -982.62% | -65.13% | -217.05% | -569.36% | -3,776.61% | -37,030.66% | -4,190.46% | -466,936.68% | -416,112.49% | -65,509.12% | -71,415.40% | -78,353.34% | -83,266.70% | -54.36% | -24.91% | -60.24% | 0.23% | 17.08% | -44.41% | -487.63% | -494.19% | -1,969.38% | -1,050.00% | -1,211.11% | -7,900.00% | -2,800.00% |
| Income Tax Expense | 0.00 | 16.04K | -81.74K | 707.00 | 2.75K | -4.06M | -648.00K | -436.05K | 2.68M | 2.37M | 43.33M | -7.88M | 43.65M | 37.45M | 2.12M | -32.20M | 1.28M | 1.28M | 1.54M | 187.87K | -726.00 | 2.62K | -194.07K | -407.40K | -435.54K | -4.02M | -2.37M | 400.00K | 200.00K | 0.00 | -200.00K |
| Net Income | -15.18M | -11.73M | -10.64M | -10.95M | -16.13M | 74.95M | -14.31M | -27.56M | -35.73M | -42.70M | -29.16M | 5.61M | -49.96M | -39.61M | -5.17M | -5.09M | -4.74M | -4.93M | -3.54M | -1.80M | -2.96M | 14.95K | 1.84M | -4.17M | -28.03M | -23.25M | -20.97M | -10.80M | -10.80M | -8.00M | -2.60M |
| Net Income Ratio | -23,117.58% | -2,207.08% | -1,162.82% | -41,120.85% | -5,000.12% | 4,139.67% | -65.13% | -208.03% | -569.36% | -3,776.61% | -37,030.66% | 939.05% | -466.94% | -416.11% | -65.51% | -71.42% | -78.35% | -83.27% | -59.49% | -27.63% | -60.23% | 0.20% | 18.95% | -44.19% | -480.61% | -453.33% | -1,790.42% | -1,080.00% | -1,200.00% | -8,000.00% | -2,600.00% |
| EPS | -0.59 | -0.40 | -0.45 | -0.76 | -1.89 | 9.40 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.45 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| EPS Diluted | -0.56 | -0.40 | -0.45 | -0.76 | -1.89 | 9.00 | -1.84 | -3.65 | -4.80 | -7.01 | -5.89 | 1.20 | -12.38 | -10.74 | -1.51 | -1.62 | -1.62 | -1.69 | -1.25 | -0.89 | -1.64 | 0.01 | 0.80 | -3.63 | -24.54 | -20.31 | -21.17 | -15.55 | -23.60 | -22.60 | -8.20 |
| Weighted Avg Shares Out | 29.34M | 29.34M | 23.90M | 14.39M | 8.53M | 8.08M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.29M | 1.29M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
| Weighted Avg Shares Out (Dil) | 30.90M | 29.34M | 23.90M | 14.39M | 8.53M | 8.30M | 7.77M | 7.56M | 7.44M | 6.09M | 4.95M | 4.53M | 4.04M | 3.69M | 3.43M | 3.15M | 2.93M | 2.92M | 2.84M | 2.02M | 1.80M | 1.30M | 1.32M | 1.15M | 1.14M | 1.14M | 990.57K | 694.44K | 457.63K | 353.98K | 317.07K |
Navidea Biopharmaceuticals Reports Second Quarter 2021 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June...
Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, August 11, 2021 at...
Navidea Biopharmaceuticals to Host Second Quarter 2021 Earnings Conference Call and Business Update
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, August 11, 2021 at...
Navidea Biopharmaceuticals Announces First 110 Subjects Imaged in NAV3-35 Normative Database Phase 2b Study to Support Rheumatoid Arthritis Indications
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that over 110 subjects have been enrolled and imaged in its NAV3-35 Phase 2b...
NAVB Stock Increases Over 9% Pre-Market: Why It Happened
The stock price of Navidea Biopharmaceuticals Inc (NYSEAMERICAN: NAVB) increased by over 9% pre-market. This is why it happened.
Navidea Biopharmaceuticals Announces End-of-Phase 2 Type B Meeting Request Granted by the FDA to Discuss Ongoing Clinical Program in Rheumatoid Arthritis
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the U.S. Food and Drug Administration (“FDA”) has granted the Company's request for...
Macrophage Therapeutics, Inc. Wins Delaware Case Against Michael Goldberg for Breach of Fiduciary Duty
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on June 23, 2021, Vice Chancellor Joseph Slights of the Court of Chancery...
Navidea Biopharmaceuticals Announces Issuance of U.S. Patent for Diagnosis and Treatment of Viral Infections
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the U.S. Patent and Trademark Office (“USPTO”) issued to Navidea U.S. patent 11,007,272,...
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2021 Results - Earnings Call Transcript
Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q1 2021 Results - Earnings Call Transcript
Navidea Biopharmaceuticals Reports First Quarter 2021 Financial Results
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the first quarter for the period ended March 31, 2021....
Source: https://incomestatements.info
Category: Stock Reports